Study points to new target for treating aggressive brain cancer
Glioblastoma remains one of the deadliest cancers, with limited treatment advances and tumors that often resist radiation and chemotherapy. New research from The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute points to SET as a potential target for making glioblastoma cells more vulnerable to treatment.
A recent study from The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified SET as a potential new target for treating aggressive brain cancer, specifically glioblastoma. Researchers discovered that suppressing SET in preclinical models prevented tumor formation and made glioblastoma cells more sensitive to radiation.
By blocking related proteins, the cancer cells also became more susceptible to radiation treatment. The study's findings suggest that targeting the PP2A pathway, which is suppressed by SET in glioblastoma cells, could make existing treatments more effective. However, the research is still in its preliminary stages and has not been tested in patients.
The next step is to determine whether targeting SET or related PP2A-blocking proteins can be done safely and whether it improves the response to standard glioblastoma treatment.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.
